Management Change/Compensation (Form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 14, 2026, Change Agents Corporation (the "Company") appointed Eric Weisblum as an independent director on the Company's board of directors, effective October 12, 2026. Mr. Weisblum will serve on each of the Audit, Compensation and Nominating and Corporate Governance Committees.

Eric Weisblum brings decades of investment banking, capital markets and public company management experience. Since 2020 Mr. Weisblum has been the Chief Executive Officer of Silo Pharma Inc, a biopharmaceutical company that he founded. Prior to Silo Pharma Mr. Weisblum was a private investor, board member, and advisor to several companies. Mr. Weisblum has experience in both licensing therapeutic assets and assisting in their development. As a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring and trading financial instruments. Mr. Weisblum was a registered representative with Domestic Securities, a New Jersey-based broker-dealer. While with Domestic Securities, Mr. Weisblum held the Series 7 - General Securities Representative, the Series 63 - Uniform Securities Agent State Law Examination, and the Series 55 - Registered Equity Trader securities registrations. From 1993 to 2002, Mr. Weisblum originated, structured, traded, and placed structured financing transactions at M.H. Meyerson & Co. Inc., a publicly-traded registered investment bank. He holds a B.A. from the University of Hartford's Barney School of Business.

The Company believes Mr. Weinblum is suited to act as a Company Director due to his significant public company and capital markets experience.

There is no arrangement or understanding between Mr. Weisblum and any other person, other than the Company's directors acting solely in their capacity as such, pursuant to which he was selected as a director of the Company. Mr. Weisblum is not related by blood, marriage or adoption to any director or executive officer.

The Company is not aware of any transaction, or currently proposed transaction, in which the Company was or is to be a participant and in which Mr. Weisblum, or any member of his immediate family, had or will have a direct or indirect material interest that would be required to be reported under Item 404(a) of Regulation S-K.